production of radioisotopes for medical applications at riamantica/radio-ria/ruth_radioria.pdf ·...
TRANSCRIPT
![Page 1: Production of Radioisotopes for Medical Applications at RIAmantica/radio-ria/ruth_radioria.pdf · Production of Radioisotopes for Medical Applications at RIA Thomas J. Ruth TRIUMF](https://reader030.vdocument.in/reader030/viewer/2022021715/5c2b995809d3f2af358cb508/html5/thumbnails/1.jpg)
27 March 2003 RIA, DNCT, New Orleans ACSTJ Ruth
Production of Radioisotopes for Medical Applications at RIA
Thomas J. RuthTRIUMF
![Page 2: Production of Radioisotopes for Medical Applications at RIAmantica/radio-ria/ruth_radioria.pdf · Production of Radioisotopes for Medical Applications at RIA Thomas J. Ruth TRIUMF](https://reader030.vdocument.in/reader030/viewer/2022021715/5c2b995809d3f2af358cb508/html5/thumbnails/2.jpg)
27 March 2003 RIA, DNCT, New Orleans ACSTJ Ruth
The advances in Nuclear Medicine during the next decade will be in the use of radiotoxic nuclides for therapy.
To make the best use of these isotopes they must be prepared in high specific activity.
![Page 3: Production of Radioisotopes for Medical Applications at RIAmantica/radio-ria/ruth_radioria.pdf · Production of Radioisotopes for Medical Applications at RIA Thomas J. Ruth TRIUMF](https://reader030.vdocument.in/reader030/viewer/2022021715/5c2b995809d3f2af358cb508/html5/thumbnails/3.jpg)
27 March 2003 RIA, DNCT, New Orleans ACSTJ Ruth
What role can RIA play?
• Source for unique radiotoxic nuclides for radioisotope therapy (RIT).
• Demonstrating the efficacy of high specific activity radioisotopes.
• Implantation of radiotoxic nuclides.
![Page 4: Production of Radioisotopes for Medical Applications at RIAmantica/radio-ria/ruth_radioria.pdf · Production of Radioisotopes for Medical Applications at RIA Thomas J. Ruth TRIUMF](https://reader030.vdocument.in/reader030/viewer/2022021715/5c2b995809d3f2af358cb508/html5/thumbnails/4.jpg)
27 March 2003 RIA, DNCT, New Orleans ACSTJ Ruth
Cell killing and DNA damage
• Tumor control and normal tissue injury by IR both depend on cell killing.
• Cell killing is caused primarily by damage to genomic DNA.
4
![Page 5: Production of Radioisotopes for Medical Applications at RIAmantica/radio-ria/ruth_radioria.pdf · Production of Radioisotopes for Medical Applications at RIA Thomas J. Ruth TRIUMF](https://reader030.vdocument.in/reader030/viewer/2022021715/5c2b995809d3f2af358cb508/html5/thumbnails/5.jpg)
27 March 2003 RIA, DNCT, New Orleans ACSTJ Ruth
Radiation therapy (XRT)•A number of approaches to therapeutic radiation delivery:Regional: External beam (EB-XRT)
Sealed source (brachytherapy)Systemic: Unsealed source (radionuclide therapy)
Targeted radioisotope therapy, e.g., with antibodies (radioimmunotherapy).
•The ideal agent for systemic XRT would localize uniformly in tumor cells and carry isotopes that emit radiations with penetration of cellular dimensions, thereby minimizing dose to normal tissue.
![Page 6: Production of Radioisotopes for Medical Applications at RIAmantica/radio-ria/ruth_radioria.pdf · Production of Radioisotopes for Medical Applications at RIA Thomas J. Ruth TRIUMF](https://reader030.vdocument.in/reader030/viewer/2022021715/5c2b995809d3f2af358cb508/html5/thumbnails/6.jpg)
27 March 2003 RIA, DNCT, New Orleans ACSTJ Ruth
Regional versus systemic XRT•Systemic therapy differs from EB-XRT in 2 major ways:1. Dose rate [high dose rate (HDR) and constant, versus low dose rate (LDR) and declining.2. Heterogeneity of dose distribution (especially in large tumors with poor vascularization and hypoxic regions). This makes tumor control more difficult because of cold regions of radionuclide deposition.•Most of our radiobiological understanding has come from homogeneous exposures to large single doses or fractionated doses of ionizing radiation (IR).
![Page 7: Production of Radioisotopes for Medical Applications at RIAmantica/radio-ria/ruth_radioria.pdf · Production of Radioisotopes for Medical Applications at RIA Thomas J. Ruth TRIUMF](https://reader030.vdocument.in/reader030/viewer/2022021715/5c2b995809d3f2af358cb508/html5/thumbnails/7.jpg)
27 March 2003 RIA, DNCT, New Orleans ACSTJ Ruth
![Page 8: Production of Radioisotopes for Medical Applications at RIAmantica/radio-ria/ruth_radioria.pdf · Production of Radioisotopes for Medical Applications at RIA Thomas J. Ruth TRIUMF](https://reader030.vdocument.in/reader030/viewer/2022021715/5c2b995809d3f2af358cb508/html5/thumbnails/8.jpg)
27 March 2003 RIA, DNCT, New Orleans ACSTJ Ruth
IR induces clusters of ionizations and of DNA-damaging events
α
β
•The complexity of the cluster depends strongly on the LET of the incident ionizing species.
![Page 9: Production of Radioisotopes for Medical Applications at RIAmantica/radio-ria/ruth_radioria.pdf · Production of Radioisotopes for Medical Applications at RIA Thomas J. Ruth TRIUMF](https://reader030.vdocument.in/reader030/viewer/2022021715/5c2b995809d3f2af358cb508/html5/thumbnails/9.jpg)
27 March 2003 RIA, DNCT, New Orleans ACSTJ Ruth
Isotopes commonly used in systemic therapy
•Important features : half time, penetration (type and LET of emission).
![Page 10: Production of Radioisotopes for Medical Applications at RIAmantica/radio-ria/ruth_radioria.pdf · Production of Radioisotopes for Medical Applications at RIA Thomas J. Ruth TRIUMF](https://reader030.vdocument.in/reader030/viewer/2022021715/5c2b995809d3f2af358cb508/html5/thumbnails/10.jpg)
27 March 2003 RIA, DNCT, New Orleans ACSTJ Ruth
Which Isotope?
range [mm]
10-2 10-1 100 101 102
1.7 MeV β-
0.15 MeV β-
5.3 MeV α
AUGER-electrons
64Cu
131I
90Y
64Cu
211At
![Page 11: Production of Radioisotopes for Medical Applications at RIAmantica/radio-ria/ruth_radioria.pdf · Production of Radioisotopes for Medical Applications at RIA Thomas J. Ruth TRIUMF](https://reader030.vdocument.in/reader030/viewer/2022021715/5c2b995809d3f2af358cb508/html5/thumbnails/11.jpg)
27 March 2003 RIA, DNCT, New Orleans ACSTJ Ruth
Candidate radionuclides forradioimmunotherapy: 47Sc 64Cu 67Cu
90Y 105Rh 103Pd
111Ag 124I 142Pr
149Pm 153Sm 159Gd
166Ho 177Lu 186/188Re
194Ir 193m,195mPt 211At
![Page 12: Production of Radioisotopes for Medical Applications at RIAmantica/radio-ria/ruth_radioria.pdf · Production of Radioisotopes for Medical Applications at RIA Thomas J. Ruth TRIUMF](https://reader030.vdocument.in/reader030/viewer/2022021715/5c2b995809d3f2af358cb508/html5/thumbnails/12.jpg)
27 March 2003 RIA, DNCT, New Orleans ACSTJ Ruth
Yields from direct bombardment of UC2 with 500 MeV p
193m,195mPt
186Re, 188W
142Pr10-3
10-6
atoms p-1
![Page 13: Production of Radioisotopes for Medical Applications at RIAmantica/radio-ria/ruth_radioria.pdf · Production of Radioisotopes for Medical Applications at RIA Thomas J. Ruth TRIUMF](https://reader030.vdocument.in/reader030/viewer/2022021715/5c2b995809d3f2af358cb508/html5/thumbnails/13.jpg)
27 March 2003 RIA, DNCT, New Orleans ACSTJ Ruth
Direct production yields are probably too low!
![Page 14: Production of Radioisotopes for Medical Applications at RIAmantica/radio-ria/ruth_radioria.pdf · Production of Radioisotopes for Medical Applications at RIA Thomas J. Ruth TRIUMF](https://reader030.vdocument.in/reader030/viewer/2022021715/5c2b995809d3f2af358cb508/html5/thumbnails/14.jpg)
27 March 2003 RIA, DNCT, New Orleans ACSTJ Ruth
Typically, high energy reactions favor the proton rich isotopes. However these spallation type reactions are accompanied by large amounts of secondary protons and neutrons.
![Page 15: Production of Radioisotopes for Medical Applications at RIAmantica/radio-ria/ruth_radioria.pdf · Production of Radioisotopes for Medical Applications at RIA Thomas J. Ruth TRIUMF](https://reader030.vdocument.in/reader030/viewer/2022021715/5c2b995809d3f2af358cb508/html5/thumbnails/15.jpg)
27 March 2003 RIA, DNCT, New Orleans ACSTJ Ruth
2º Proton spectrum from from 500 MeV p on Ta
![Page 16: Production of Radioisotopes for Medical Applications at RIAmantica/radio-ria/ruth_radioria.pdf · Production of Radioisotopes for Medical Applications at RIA Thomas J. Ruth TRIUMF](https://reader030.vdocument.in/reader030/viewer/2022021715/5c2b995809d3f2af358cb508/html5/thumbnails/16.jpg)
27 March 2003 RIA, DNCT, New Orleans ACSTJ Ruth
Neutron spectrum from 500 MeV p on Ta
![Page 17: Production of Radioisotopes for Medical Applications at RIAmantica/radio-ria/ruth_radioria.pdf · Production of Radioisotopes for Medical Applications at RIA Thomas J. Ruth TRIUMF](https://reader030.vdocument.in/reader030/viewer/2022021715/5c2b995809d3f2af358cb508/html5/thumbnails/17.jpg)
27 March 2003 RIA, DNCT, New Orleans ACSTJ Ruth
Therefore, how can we take advantage of this additional source of isotope production?
![Page 18: Production of Radioisotopes for Medical Applications at RIAmantica/radio-ria/ruth_radioria.pdf · Production of Radioisotopes for Medical Applications at RIA Thomas J. Ruth TRIUMF](https://reader030.vdocument.in/reader030/viewer/2022021715/5c2b995809d3f2af358cb508/html5/thumbnails/18.jpg)
27 March 2003 RIA, DNCT, New Orleans ACSTJ Ruth
2 Stage Concept
1º Target
Cooling water2º Target
![Page 19: Production of Radioisotopes for Medical Applications at RIAmantica/radio-ria/ruth_radioria.pdf · Production of Radioisotopes for Medical Applications at RIA Thomas J. Ruth TRIUMF](https://reader030.vdocument.in/reader030/viewer/2022021715/5c2b995809d3f2af358cb508/html5/thumbnails/19.jpg)
27 March 2003 RIA, DNCT, New Orleans ACSTJ Ruth
A 2 stage target may be able to be operated in parasitic mode and can be tailored to the radioisotopes of interest. Many of the radioisotopes of interest are only a few neutrons off the line of stability.
![Page 20: Production of Radioisotopes for Medical Applications at RIAmantica/radio-ria/ruth_radioria.pdf · Production of Radioisotopes for Medical Applications at RIA Thomas J. Ruth TRIUMF](https://reader030.vdocument.in/reader030/viewer/2022021715/5c2b995809d3f2af358cb508/html5/thumbnails/20.jpg)
27 March 2003 RIA, DNCT, New Orleans ACSTJ Ruth
S. Katcoff, BNL
![Page 21: Production of Radioisotopes for Medical Applications at RIAmantica/radio-ria/ruth_radioria.pdf · Production of Radioisotopes for Medical Applications at RIA Thomas J. Ruth TRIUMF](https://reader030.vdocument.in/reader030/viewer/2022021715/5c2b995809d3f2af358cb508/html5/thumbnails/21.jpg)
27 March 2003 RIA, DNCT, New Orleans ACSTJ Ruth
Some examples...
• 51V(n,2p3n)47Sc (99.75% nat. abund.)• 69Ga(n,2pn)67Cu (60% nat. abund.)• 107Ag(n,2pn)105Rh (52% nat. abund.)• 169Tm(n,2p2n/α)166Ho (100% nat.
abund.)• 181Ta(n,2p3n)177Lu (99.988% nat. abund.)
![Page 22: Production of Radioisotopes for Medical Applications at RIAmantica/radio-ria/ruth_radioria.pdf · Production of Radioisotopes for Medical Applications at RIA Thomas J. Ruth TRIUMF](https://reader030.vdocument.in/reader030/viewer/2022021715/5c2b995809d3f2af358cb508/html5/thumbnails/22.jpg)
27 March 2003 RIA, DNCT, New Orleans ACSTJ Ruth
S. Katcoff, BNL
![Page 23: Production of Radioisotopes for Medical Applications at RIAmantica/radio-ria/ruth_radioria.pdf · Production of Radioisotopes for Medical Applications at RIA Thomas J. Ruth TRIUMF](https://reader030.vdocument.in/reader030/viewer/2022021715/5c2b995809d3f2af358cb508/html5/thumbnails/23.jpg)
27 March 2003 RIA, DNCT, New Orleans ACSTJ Ruth
S. Katcoff, BNL
![Page 24: Production of Radioisotopes for Medical Applications at RIAmantica/radio-ria/ruth_radioria.pdf · Production of Radioisotopes for Medical Applications at RIA Thomas J. Ruth TRIUMF](https://reader030.vdocument.in/reader030/viewer/2022021715/5c2b995809d3f2af358cb508/html5/thumbnails/24.jpg)
27 March 2003 RIA, DNCT, New Orleans ACSTJ Ruth
Perhaps a route to the highly sought after platinum isotopes…
197Au(n,pxn)193m,195mPtx = 2,4
While additional isotopes of Pt are formed such as 194,196Pt, the SA is still better than
from n-capture.
![Page 25: Production of Radioisotopes for Medical Applications at RIAmantica/radio-ria/ruth_radioria.pdf · Production of Radioisotopes for Medical Applications at RIA Thomas J. Ruth TRIUMF](https://reader030.vdocument.in/reader030/viewer/2022021715/5c2b995809d3f2af358cb508/html5/thumbnails/25.jpg)
27 March 2003 RIA, DNCT, New Orleans ACSTJ Ruth
And what about co-production of isotopes?
On-line isotope separators!
![Page 26: Production of Radioisotopes for Medical Applications at RIAmantica/radio-ria/ruth_radioria.pdf · Production of Radioisotopes for Medical Applications at RIA Thomas J. Ruth TRIUMF](https://reader030.vdocument.in/reader030/viewer/2022021715/5c2b995809d3f2af358cb508/html5/thumbnails/26.jpg)
27 March 2003 RIA, DNCT, New Orleans ACSTJ Ruth
ISOL produced RadionuclidesUniversality:
Spallation reaction provides the access to any radionuclide we want, with respect to of type and energy of radiation and half-life
Purity:isotopically separated and carrier free
Ion Energy:ion energy is usually between 30 and 60 kV, implantation technique opens a new field of application
![Page 27: Production of Radioisotopes for Medical Applications at RIAmantica/radio-ria/ruth_radioria.pdf · Production of Radioisotopes for Medical Applications at RIA Thomas J. Ruth TRIUMF](https://reader030.vdocument.in/reader030/viewer/2022021715/5c2b995809d3f2af358cb508/html5/thumbnails/27.jpg)
27 March 2003 RIA, DNCT, New Orleans ACSTJ Ruth
Reactor produced radionuclides that potentially could be prepared via on-line
isotope separator system:
105Rh 109Pd 111Ag
142Pr 149Pm 153Sm
159Gd 166Ho 177Lu
186Re 188Re 194Ir
![Page 28: Production of Radioisotopes for Medical Applications at RIAmantica/radio-ria/ruth_radioria.pdf · Production of Radioisotopes for Medical Applications at RIA Thomas J. Ruth TRIUMF](https://reader030.vdocument.in/reader030/viewer/2022021715/5c2b995809d3f2af358cb508/html5/thumbnails/28.jpg)
27 March 2003 RIA, DNCT, New Orleans ACSTJ Ruth
Production of Selected Isotope
Isotope ISOLDE Yield(atoms/µA /s)
Projected ISAC YieldmCi/100 µA day
105Rh 1.5 x 108 190 109Pd 2.4 x 109 790 142Pr 1 x 107 23
149Pm 4.3 X 105 0.4 153Sm 8.7 x 107 83
![Page 29: Production of Radioisotopes for Medical Applications at RIAmantica/radio-ria/ruth_radioria.pdf · Production of Radioisotopes for Medical Applications at RIA Thomas J. Ruth TRIUMF](https://reader030.vdocument.in/reader030/viewer/2022021715/5c2b995809d3f2af358cb508/html5/thumbnails/29.jpg)
27 March 2003 RIA, DNCT, New Orleans ACSTJ Ruth
What about in-situ production and release?
![Page 30: Production of Radioisotopes for Medical Applications at RIAmantica/radio-ria/ruth_radioria.pdf · Production of Radioisotopes for Medical Applications at RIA Thomas J. Ruth TRIUMF](https://reader030.vdocument.in/reader030/viewer/2022021715/5c2b995809d3f2af358cb508/html5/thumbnails/30.jpg)
27 March 2003 RIA, DNCT, New Orleans ACSTJ Ruth
211At Production t1/2 = 7.2 h
• Possible reactions– 209Bi(α,2n) @ 28 MeV– 209Bi(7Li,5n)211Rn @ 60 MeV– 232Th(p,spall.)211Rn @ >200 MeV
• 211Rn t1/2 = 14.6 h
![Page 31: Production of Radioisotopes for Medical Applications at RIAmantica/radio-ria/ruth_radioria.pdf · Production of Radioisotopes for Medical Applications at RIA Thomas J. Ruth TRIUMF](https://reader030.vdocument.in/reader030/viewer/2022021715/5c2b995809d3f2af358cb508/html5/thumbnails/31.jpg)
27 March 2003 RIA, DNCT, New Orleans ACSTJ Ruth
Decay of 211Rn and growth of 211At
![Page 32: Production of Radioisotopes for Medical Applications at RIAmantica/radio-ria/ruth_radioria.pdf · Production of Radioisotopes for Medical Applications at RIA Thomas J. Ruth TRIUMF](https://reader030.vdocument.in/reader030/viewer/2022021715/5c2b995809d3f2af358cb508/html5/thumbnails/32.jpg)
27 March 2003 RIA, DNCT, New Orleans ACSTJ Ruth
Estimated Production of 211Rn
• Target - UO2/C - 3.4 g• Yield of 211Rn - 1.5 x 107nuclei/s/µA• Translates to 0.027 mCi/h
Conclusion - Need at least 3 orders of magnitude improvement to have any clinical utility.
![Page 33: Production of Radioisotopes for Medical Applications at RIAmantica/radio-ria/ruth_radioria.pdf · Production of Radioisotopes for Medical Applications at RIA Thomas J. Ruth TRIUMF](https://reader030.vdocument.in/reader030/viewer/2022021715/5c2b995809d3f2af358cb508/html5/thumbnails/33.jpg)
27 March 2003 RIA, DNCT, New Orleans ACSTJ Ruth
• 100 µA provides 2 orders of magnitude,• thicker target/beam optics gains a factor
of 2 or 3 (or more),• better transport system from target to
ECR gains a factor of 2 at most,• better ionization efficiency could
provide another factor of 2 or 3.
![Page 34: Production of Radioisotopes for Medical Applications at RIAmantica/radio-ria/ruth_radioria.pdf · Production of Radioisotopes for Medical Applications at RIA Thomas J. Ruth TRIUMF](https://reader030.vdocument.in/reader030/viewer/2022021715/5c2b995809d3f2af358cb508/html5/thumbnails/34.jpg)
27 March 2003 RIA, DNCT, New Orleans ACSTJ Ruth
Implantation Research• + ions implanted with 60 keV into
different backings:• - Mylar foils• - filter paper• - polyethylene foil• - aluminum foil• - Other metals and shapes
![Page 35: Production of Radioisotopes for Medical Applications at RIAmantica/radio-ria/ruth_radioria.pdf · Production of Radioisotopes for Medical Applications at RIA Thomas J. Ruth TRIUMF](https://reader030.vdocument.in/reader030/viewer/2022021715/5c2b995809d3f2af358cb508/html5/thumbnails/35.jpg)
27 March 2003 RIA, DNCT, New Orleans ACSTJ Ruth
Implantation
ION BEAM
60 keV
Implantation into plastic material open channelsmetal foils channels closedII
P l a s t i c – f o i l (PE, polyether, MYLAR, KAPTON …)
![Page 36: Production of Radioisotopes for Medical Applications at RIAmantica/radio-ria/ruth_radioria.pdf · Production of Radioisotopes for Medical Applications at RIA Thomas J. Ruth TRIUMF](https://reader030.vdocument.in/reader030/viewer/2022021715/5c2b995809d3f2af358cb508/html5/thumbnails/36.jpg)
27 March 2003 RIA, DNCT, New Orleans ACSTJ Ruth
max implantation density: 2x1013
Rb+cm-2
2x1013 81Rb-ions = 1 GBq 81Rb
A 5 mm long tip of a Catheter with d = 3.5 mm can stable carry 0.5 GBq 81Rb.
Blood acts as eluting agent!
for in vivo use
Implantation Type 18Rb / 81mKr Generator
![Page 37: Production of Radioisotopes for Medical Applications at RIAmantica/radio-ria/ruth_radioria.pdf · Production of Radioisotopes for Medical Applications at RIA Thomas J. Ruth TRIUMF](https://reader030.vdocument.in/reader030/viewer/2022021715/5c2b995809d3f2af358cb508/html5/thumbnails/37.jpg)
27 March 2003 RIA, DNCT, New Orleans ACSTJ Ruth
Feasibility of 125Xe Implantation at TRIUMF for the Preparation of 125I Brachytherapy Sources
![Page 38: Production of Radioisotopes for Medical Applications at RIAmantica/radio-ria/ruth_radioria.pdf · Production of Radioisotopes for Medical Applications at RIA Thomas J. Ruth TRIUMF](https://reader030.vdocument.in/reader030/viewer/2022021715/5c2b995809d3f2af358cb508/html5/thumbnails/38.jpg)
27 March 2003 RIA, DNCT, New Orleans ACSTJ Ruth
Critical Factors on 125I Implantation
• Production rates of 125Xe• Implant system efficiency• Stability from losses of implanted species • Radiobiological effectiveness
![Page 39: Production of Radioisotopes for Medical Applications at RIAmantica/radio-ria/ruth_radioria.pdf · Production of Radioisotopes for Medical Applications at RIA Thomas J. Ruth TRIUMF](https://reader030.vdocument.in/reader030/viewer/2022021715/5c2b995809d3f2af358cb508/html5/thumbnails/39.jpg)
27 March 2003 RIA, DNCT, New Orleans ACSTJ Ruth
Conclusions
• System efficiency = 23%• Cs target has high production rate• Estimated yields = 2 mCi/hour• Stable implant
![Page 40: Production of Radioisotopes for Medical Applications at RIAmantica/radio-ria/ruth_radioria.pdf · Production of Radioisotopes for Medical Applications at RIA Thomas J. Ruth TRIUMF](https://reader030.vdocument.in/reader030/viewer/2022021715/5c2b995809d3f2af358cb508/html5/thumbnails/40.jpg)
27 March 2003 RIA, DNCT, New Orleans ACSTJ Ruth
Many clinically relevant therapeutic nuclides can not be produced in high specific activity from reactors and the accelerators can not produce sufficient quantities for large scale usage.
![Page 41: Production of Radioisotopes for Medical Applications at RIAmantica/radio-ria/ruth_radioria.pdf · Production of Radioisotopes for Medical Applications at RIA Thomas J. Ruth TRIUMF](https://reader030.vdocument.in/reader030/viewer/2022021715/5c2b995809d3f2af358cb508/html5/thumbnails/41.jpg)
27 March 2003 RIA, DNCT, New Orleans ACSTJ Ruth
Problem
• Reactor production - Low Specific Activity.• National Lab Accelerators - Capacity for
large scale production insufficient.
![Page 42: Production of Radioisotopes for Medical Applications at RIAmantica/radio-ria/ruth_radioria.pdf · Production of Radioisotopes for Medical Applications at RIA Thomas J. Ruth TRIUMF](https://reader030.vdocument.in/reader030/viewer/2022021715/5c2b995809d3f2af358cb508/html5/thumbnails/42.jpg)
27 March 2003 RIA, DNCT, New Orleans ACSTJ Ruth
Possible Solution:
Production in reactors or spallation sources with off-line isotope separation.
![Page 43: Production of Radioisotopes for Medical Applications at RIAmantica/radio-ria/ruth_radioria.pdf · Production of Radioisotopes for Medical Applications at RIA Thomas J. Ruth TRIUMF](https://reader030.vdocument.in/reader030/viewer/2022021715/5c2b995809d3f2af358cb508/html5/thumbnails/43.jpg)
27 March 2003 RIA, DNCT, New Orleans ACSTJ Ruth
Conclusions
• Many radionuclides can be produced at low energy cyclotrons distributed throughout NA, Europe and Asia.
• High Energy facilities can not be relied upon for the bulk of clinically relevant radionuclides.
• Alternative methods of production and isolation need to be explored.
![Page 44: Production of Radioisotopes for Medical Applications at RIAmantica/radio-ria/ruth_radioria.pdf · Production of Radioisotopes for Medical Applications at RIA Thomas J. Ruth TRIUMF](https://reader030.vdocument.in/reader030/viewer/2022021715/5c2b995809d3f2af358cb508/html5/thumbnails/44.jpg)
27 March 2003 RIA, DNCT, New Orleans ACSTJ Ruth
Conclusions continued…
RIA can help define these methods through access to radioisotopes, in high specific activity, that are not readily available elsewhere.
![Page 45: Production of Radioisotopes for Medical Applications at RIAmantica/radio-ria/ruth_radioria.pdf · Production of Radioisotopes for Medical Applications at RIA Thomas J. Ruth TRIUMF](https://reader030.vdocument.in/reader030/viewer/2022021715/5c2b995809d3f2af358cb508/html5/thumbnails/45.jpg)
27 March 2003 RIA, DNCT, New Orleans ACSTJ Ruth
However, as is the situation today, RIA will face the same issues that existinghigh energy radioisotope sources in itsability to serve as a source of radiotracers.
![Page 46: Production of Radioisotopes for Medical Applications at RIAmantica/radio-ria/ruth_radioria.pdf · Production of Radioisotopes for Medical Applications at RIA Thomas J. Ruth TRIUMF](https://reader030.vdocument.in/reader030/viewer/2022021715/5c2b995809d3f2af358cb508/html5/thumbnails/46.jpg)
27 March 2003 RIA, DNCT, New Orleans ACSTJ Ruth
Limitations of High Energy Facilities
• Availability• Scheduling• Range of products (not an issue for RIA)• Sp. Act. affected by co-production of
isotopes (not an issue with ISOL)• Reliability
![Page 47: Production of Radioisotopes for Medical Applications at RIAmantica/radio-ria/ruth_radioria.pdf · Production of Radioisotopes for Medical Applications at RIA Thomas J. Ruth TRIUMF](https://reader030.vdocument.in/reader030/viewer/2022021715/5c2b995809d3f2af358cb508/html5/thumbnails/47.jpg)
27 March 2003 RIA, DNCT, New Orleans ACSTJ Ruth
In spite of these limitations RIA radioisotopeproduction capacity will make it an importantcomponent in both Biomedical Research butalso in bringing radiotracers to the Health Care of North Americans and beyond.
![Page 48: Production of Radioisotopes for Medical Applications at RIAmantica/radio-ria/ruth_radioria.pdf · Production of Radioisotopes for Medical Applications at RIA Thomas J. Ruth TRIUMF](https://reader030.vdocument.in/reader030/viewer/2022021715/5c2b995809d3f2af358cb508/html5/thumbnails/48.jpg)
27 March 2003 RIA, DNCT, New Orleans ACSTJ Ruth
Acknowledgements
I wish to thank the many colleagues have contributed to the work, ideas and/or slides presented here, especially Gerd Beyer, Geneva, Lutz Moritz, TRIUMF, Suzanne Smith, ANSTO and John Vincent, TRIUMF.
• This work supported by the TRIUMF Life Science Program. TRIUMF is funded through a contribution from the National Research Council of Canada.